The National Pharmaceutical Pricing Authority (NPPA) has announced a significant revision to the maximum retail prices (MRPs) of 543 anti-cancer drug brands. These new prices are set to come into effect from November 9, marking a crucial step towards making cancer treatment more accessible and affordable across India.
Government's Move to Rationalize Drug Costs
This initiative stems from the government's earlier decision to rationalize trade margins on 137 non-scheduled anti-cancer drugs. By capping these margins, the aim is to curb excessive pricing throughout the supply chain, ultimately reducing the financial burden on patients and their families.
The revised price list, published by the NPPA under the Department of Pharmaceuticals, Ministry of Chemicals and Fertilizers, incorporates pricing information submitted by pharmaceutical companies up to October 27, 2026. The authority has indicated that this list will be continuously updated as manufacturers submit further revised prices for non-scheduled anti-cancer medicines.
Impact on Patients and Covered Medicines
For individuals undergoing long-term cancer treatment, the cost of medicines often represents a substantial financial strain. The newly revised MRPs are specifically designed to alleviate this burden, improving both the affordability and accessibility of essential cancer therapies.
The trade margin rationalization covers a broad spectrum of anti-cancer drugs, including those used to treat various cancer types and manage associated complications. Examples include immunotherapy medicines, Denosumab (used for breast and prostate cancer), Pegfilgrastim (to prevent neutropenia), and Bevacizumab (approved for colon, ovarian, and cervical cancers).
Patients and their families are encouraged to consult the updated list to verify the applicable maximum retail prices for their specific medications, as not all anti-cancer drugs will necessarily see the same degree of price adjustment.